(Q73740291)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Potential role of abciximab in ischemic cerebrovascular disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

main subject

cerebrovascular disease

1 reference

J M Winkley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

H P Adams

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 April 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

8A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

47C-51C

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

Tissue plasminogen activator for acute ischemic stroke

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Intravenous heparin for the prevention of stroke progression in acute partial stable stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Hemorrhagic transformation in cerebral embolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Complications of acute ischaemic stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Trials of streptokinase in severe acute ischaemic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Termination of trial of streptokinase in severe acute ischaemic stroke. MAST Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900878-X

10.1016/S0002-9149(00)00878-X

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10793180%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference